Infratil Limited's 30 June 2024 independent valuation update is attached.
As noted in the attached, CDC, Longroad, Galileo, Mint, Qscan and RetireAustralia values reflect the midpoint of the 30 June independent valuations. CDC’s key valuation methodologies and assumptions were presented as part the NZX valuation announcement on 4 July 2024.
Key valuation methodologies and assumptions underpinning the remaining independent valuations are summarised in the attached and remain consistent with the 31 March 2024 valuations [1], except for Longroad (refer below), and an update for the inclusion of storage for Galileo.
The decrease in the Longroad independent valuation is largely attributable to an increase in discount rates outweighing minor positive updates to operating forecasts.
Any enquiries should be directed to:
Mark Flesher, Investor Relations, Infratil Limited
info@infratil.com
[1] 1. Valuation methodologies and assumptions for 31 March 2024 included here: https://api.nzx.com/public/announcement/431367/attachment/418814/431367-418814.pdf
Related
Australian data centre update
Infratil Limited (NZX/ASX:IFT) notes it has recently received a number of investor queries regarding power delivery timelines for under-construction sites in Australia. CDC has confirmed that it has robust delivery
Infratil Newsletter - October 2026
Attached is a copy of the latest Infratil Newsletter for investors, with commentary on our recent Investor Day and developments at various portfolio companies. Enquiries should be directed to: Brett
CDC Independent Valuation – 30 September 2026
CDC Independent Valuation – 30 September 2026 CDC’s independent valuation was broadly flat with a mid-point valuation of A$18.5 billion at 30 September 2026. Continued progress in customer contracting and